Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Jw Pharmaceutical (001060 KS)
Watchlist
38
Analysis
Health Care
•
South Korea
JW Pharmaceutical Corp manufactures prescription and over-the counter drugs. The Company produces transfusion fluids, antibiotics, anesthetics, and respiratory and circulatory medications.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
HK inno.N
•
03 Aug 2023 22:12
HK Inno.N (195940 KS): 2Q23 Result Shows Strong Sequential Improvement; K-CAB Continues to Fly High
In 2Q23, revenue increased 11% QoQ and operating profit grew 172% QoQ. K-CAB domestic revenue grew 19% QoQ. Flagship drug, K-CAB has been launched...
Tina Banerjee
Follow
450 Views
Share
bullish
•
KakaoBank
•
01 Sep 2021 07:32
KOSPI 200 September Rebalancing Results & Passive Impact Estimations
KRX officially announced the KOSPI 200 Fast Entry results of Kakao Bank and Krafton. The effective date is September 10th, so the rebalancing...
Sanghyun Park
Follow
432 Views
Share
bearish
•
KakaoBank
•
01 Sep 2021 07:14
KOSPI200 September Index Rebalance: Krafton, Kakao Bank Fast Entry Confirmed
Krafton & KakaoBank will be added to the KOSPI200 index at the close on 9 Sep, replacing Lock&Lock and JW Pharma. The inclusions will be short sell...
Brian Freitas
Follow
511 Views
Share
bearish
•
KakaoBank
•
26 Aug 2021 08:07
KOSPI200 September Rebalance Preview: Double Edged Sword
KakaoBank and Krafton are high probability inclusions to the KOSPI200 in September while Lock&Lock and JW Pharma are potential deletions. KakaoBank...
Brian Freitas
Follow
407 Views
Share
bearish
•
Jw Pharmaceutical
•
23 Aug 2021 11:58
Likely Deletes by KOSPI 200 Fast Entry on September 9: JW Pharma & Lock&Lock
This post examines the likely deletes (JW Pharma & Lock&Lock) due to the KOSPI 200 Fast Entry on September 9. It looks into the passive impact and...
Sanghyun Park
Follow
377 Views
Share
First
Previous
1
2
3
4
5
6
7
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x